Clinical Trial Update: Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy data for the ELX/TEZ/IVA triple CF therapy in participants aged 6 and older. Results were posted in May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ELX/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor) (elexacaftor/tezacaftor/ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2025-05-18